Figure 1From: Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging studyStudy disposition. Number of patients who entered and completed the study and reasons for discontinuation.Back to article page